Objectives: Diabetes is one of the most common metabolic diseases in the world. It affects 6.6% of world population and about 3 million individuals in Iran. Nowadays chemical and herbal medicines are widely prescribed to cure obesity. In Iran, cumin (Cuminum Cyminum L.) is a plant used in traditional medicine to cure obesity, and some of the new studies have suggested that cumin has a role in d...

Imagine your favourite pizza, and, after half of it is gone, your desire to eat the rest is gone as well. Sibutramine seems to have just this effect—at least for some. Doesn’t this appear like the ideal scenario for losing weight? We and other authors are not so sure about that. Sibutramine, a centrally acting monoamino (noradrenaline and serotonin) reuptake inhibitor, was originally developed ...

A novel analogue of sibutramine, 11-desisobutyl-11-benzylsibutramine, has been discovered. During routine ion mobility spectrometry (IMS) screening of a weight loss supplement collected at an US FDA import operation facility an unknown peak was observed. Further analysis of the supplement by liquid chromatography-mass spectrometry (LC-MS) and high resolution mass spectrometry revealed an unknow...

Purpose. To investigate the use of the weight-loss drugs rimonabant, sibutramine, and orlistat in primary care and to characterize the patients receiving the drugs. Methods. In this retrospective, descriptive study, 300 randomly selected patients having started weight-loss drug treatment at 15 primary care centres were investigated using the patient's medical records and their complete drug pur...

Weight management means lifestyle modification, behavioral therapy, pharmacotherapy and surgery. Drugs have wide ranging side effects and contraindication for its widespread use. Orlistat and sibutramine are the most popular in the present day context. Anti depressants especially fluoxetine is a valuable adjunct for therapy of obesity. There are many newer concepts in weight management and thes...

Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004;66:S139–44. [8] Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis. doi:10.1016/j...

This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of rimonabant for the treatment of obese or overweight patients based upon a review of the manufacturer's submission to the National Centre for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's main evidence came from fou...

No wholly successful weight-control drugs have been developed to date, despite the tremendous demand. We present an exposure-response model of sibutramine mesylate that can be applied during clinical development of other weight-control drugs. Additionally, we provide a model-based evaluation of sibutramine efficacy. Data from a double-blind, randomized, placebo-controlled, multicenter study wer...

editorial is judgment in advance of the facts Williams’s negative, even nihilistic, approach to obesity treatment and to sibutramine in particular is ill judged and inaccurate. His editorial seems to be based mainly on the limited data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT) released by the European Medicines Agency, and perhaps data not in the public domain. It would have be...

The present study assessed the potential of the sodium glucose-linked transporter (SGLT)-2 inhibitor empagliflozin to decrease body weight when administered alone or in combination with the clinically effective weight-loss agents orlistat and sibutramine in obese rats fed a cafeteria diet. Female Wistar rats were exposed to a cafeteria diet to induce obesity. Empagliflozin was dosed once daily ...